Cancer Research  09 AM Call for Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 50, 5687s-5691s, September 1, 1990]
© 1990 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dezzutti, C. S.
Right arrow Articles by Olsen, R. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dezzutti, C. S.
Right arrow Articles by Olsen, R. G.

Subunit Vaccine Protects Macaca nemestrina (Pig-tailed Macaque) against Simian T-Cell Lymphotropic Virus Type I Challenge1

Charlene S. Dezzutti2, Donald E. Frazier, Laura Y. Huff, Paul C. Stromberg and Richard G. Olsen

The Center for Retrovirus Research, Columbus, Ohio 43210 [C. S. D., P. C. S., R. G. O.], and Department of Veterinary Pathobiology, The Ohio State University, Columbus, Ohio 43210 [D. E. F., L. Y. H., P. C. S., R. G. O.]

Five macaques received two vaccinations consisting of soluble human T-cell lymphotropic virus type I proteins from a cell/serum-free human T-cell lymphotropic virus type I-producing cell line. Five other macaques were vaccine controls. All were challenged with a simian T-cell lymphotropic virus type I-producing cell line. The vaccinated macaques generated a strong serological response to challenge as opposed to the control macaques. Western blot analysis of the sera showed that both groups recognized gag and env proteins, but the vaccinate's sera reacted better to the env proteins. Additionally, the antibody produced by both groups had antibody-dependent, complement-mediated cytotoxic activity toward both human and simian T-cell lymphotropic virus type I-infected target cells. The responses of lymphocytes and neutrophils, as measured by lymphocyte blast transformation and chemiluminescence response, respectively, showed no apparent difference between the vaccinates and controls. Testing for reverse transcriptase in lymphocyte supernatants revealed that the controls contained reverse transcriptase activity, while the vaccinates remained negative. The data presented here demonstrate that the vaccine was successful in protecting Macaca nemestrina from simian T-cell lymphotropic virus type I infection.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1990 by the American Association for Cancer Research.